Search results for "SARS-CoV-2"

showing 10 items of 1204 documents

Impact of COVID-19 on global HCV elimination efforts.

2021

Background & Aims COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. Methods Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and …

0301 basic medicinePsychological interventioncoronavirusUMIC upper-middle income countriesGlobal HealthUI uncertainty intervalHIC high income countries0302 clinical medicineCost of IllnessLIC low income countriesMedicineUSA United States of AmericaLetter to the EditorMathematical modellingPWID people who inject drugsLiver DiseaseLiver DiseasesVaccinationmathematical modelingGBD Global Burden of DiseaseHepatitis CSVR sustained virologic responseEuropeHCV hepatitis C virusHepatocellular carcinomaHCVGHSS Global Health Sector StrategyRNA Viral030211 gastroenterology & hepatologyAMR region of the AmericasLiver cancerViral hepatitisHumanCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)EMR Eastern Mediterranean regionViral hepatitis eliminationviral hepatitisContext (language use)World Health OrganizationArticleWHO World Health OrganizationTime-to-Treatment03 medical and health scienceseliminationEnvironmental healthHumansLMIC lower-middle income countriesDisease EradicationDisease burdenHepatitisHepatologySARS-CoV-2business.industryWPR Western Pacific regionCOVID-19Models Theoreticalmedicine.diseaseCost of Illne030104 developmental biologySpainHCC hepatocellular carcinomabusinessJournal of hepatology
researchProduct

Different Within-Host Viral Evolution Dynamics in Severely Immunosuppressed Cases with Persistent SARS-CoV-2

2021

12 páginas, 2 figuras, 1 tabla.

0301 basic medicineQH301-705.5medicine.medical_treatment030106 microbiologyInmunologíaMedicine (miscellaneous)GenomicsSingle-nucleotide polymorphismDiseaseBiologyArticleGeneral Biochemistry Genetics and Molecular BiologyVirusdiversityPersistence03 medical and health sciencesmedicinegenomicsBiology (General)Evolutionary dynamicsimmunosuppressedDiversitySARS-CoV-2COVID-19ImmunosuppressionGenomicspersistencemedicine.diseaseVirologyviral viabilityLymphoma030104 developmental biologyImmunosuppressedViral evolutionViral viability
researchProduct

Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients

2021

COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations &gt

0301 basic medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunologyArticleSerologyPersistence (computer science)03 medical and health sciences0302 clinical medicineAntigenDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicineskin and connective tissue diseasesPharmacologyantibody concentrations.biologybusiness.industryImmunogenicitySARS-CoV-2 infectionfungiRantibody concentrationsrespiratory tract diseasesVaccinationbody regions030104 developmental biologyInfectious DiseasesImmunizationImmunologybiology.proteinMedicineAntibodybusinessCOVID-19 vaccineVaccines
researchProduct

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

2021

Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We applied a workflow of combined in silico methods (virtual drug screening, molecular docking and supervised machine learning algorithms) to identify novel drug candidates against COVID-19. We constructed chemical libraries consisting of FDA-approved drugs for drug repositioning and of natural compound datasets from literature mining and the ZINC database to select compounds interacting with SARS-CoV-2 target proteins (spike protein, nucleocapsid protein, and 2′-o-ribose methyltransferase). Supported by…

0301 basic medicineSimeprevirArtificial intelligencevirusesMERS Middle East Respiratory SyndromeHealth InformaticsBiologyMachine learningcomputer.software_genremedicine.disease_causeAntiviral AgentsArticleWHO World Health OrganizationAUC area under the curve03 medical and health sciences0302 clinical medicinessRNA single-stranded RNA virusmedicineChemotherapyHumansSARS severe acute respiratory syndromeCOVID-19 coronavirus disease 2019CoronavirusNatural productsVirtual screeningACE2 angiotensin converting enzyme 2Drug discoverybusiness.industrySARS-CoV-2COVID-19LBE lowest binding energyFDA Food and Drug AdministrationROC receiver operating characteristicComputer Science ApplicationsHIV human immunodeficiency virusMolecular Docking SimulationDrug repositioning030104 developmental biologyDrug developmentSevere acute respiratory syndrome-related coronavirusParitaprevirInfectious diseasesRespiratory virusArtificial intelligenceSupervised Machine Learningbusinesscomputer030217 neurology & neurosurgeryComputers in biology and medicine
researchProduct

Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants

2021

Abstract Background COVID-19, declared a pandemic in March 2020 by the World Health Organization is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The virus has already killed more than 2.3 million people worldwide. Object The principal intent of this work was to investigate lead compounds by screening natural product library (NPASS) for possible treatment of COVID-19. Methods Pharmacophore features were used to screen a large database to get a small dataset for structure-based virtual screening of natural product compounds. In the structure-based screening, molecular docking was performed to find a potent inhibitor molecule against the main protease (Mpro) of SARS-…

0301 basic medicineStereochemistrymedicine.medical_treatmentPhytochemicalsProtein Data Bank (RCSB PDB)Health Informaticsmedicine.disease_causeMolecular Docking SimulationAntiviral AgentsArticleDocking03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansProtease InhibitorsCoronavirusVirtual screeningNatural productsProteaseChemistrySARS-CoV-2COVID-19Computer Science ApplicationsProteaseCoronavirusMolecular Docking Simulation030104 developmental biologyDocking (molecular)PharmacophoreLead compound030217 neurology & neurosurgeryMproPeptide HydrolasesComputers in Biology and Medicine
researchProduct

Polyphosphate Reverses the Toxicity of the Quasi-Enzyme Bleomycin on Alveolar Endothelial Lung Cells In Vitro

2021

Simple Summary Bleomycin (BLM) is a medication introduced used to treat various types of cancer, including testicular cancer, ovarian cancer, and Hodgkin’s disease. Its most serious side effect is pulmonary fibrosis and impaired lung function. Using A549 human lung cells it is shown that, in parallel to an increased cell toxicity and DNA damage, BLM causes a marked enlargement of the cell nucleus. This effect is abolished by inorganic polyphosphate (polyP), if this physiological polymer is administered together with BLM. The detoxification of BLM is–most likely–caused by the upregulation of the gene encoding the BLM hydrolase which inactivates BLM in vitro and in vivo. This study contribute…

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesCancer ResearchDNA damageBleomycinlcsh:RC254-282Article03 medical and health scienceschemistry.chemical_compound0302 clinical medicineanti-SARS-CoV-2 activityDownregulation and upregulationprevention of fibrosischemistry.chemical_classificationbleomycinpulmonary fibrosisurogenital systemChemistryCell growthCOVID-19nutritional and metabolic diseasespolyphosphatelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensMolecular biologyIn vitroChromatin030104 developmental biologyEnzymeOncology030220 oncology & carcinogenesisToxicityCancers
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Mortality in COVID-19 disease patients: Correlating Association of Major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (S…

2020

Highlights • In addition to ethnicity, socio-economic factors, prior vaccinations and exposure to other coronaviruses, other factors need to be considered to explain geographical and regional variations in susceptibility, severity of clinical expression of COVID-19 disease and outcomes. • Differences in peptide binding of SARS-CoV-2 variants to MHC class II, but not to MHC class I alleles frequent in individuals with African, Asian or Caucasian descent could be identified. • Single mutations in the wildtype of SARS-CoV-2, the so called B strain or L strain impact on MHC presentation • Most likely there is selective pressure from MHC class II alleles in regard to binding of the ORF8 (L84S) v…

0301 basic medicinecross-reactivityMHC bindingPeptide bindingmedicine.disease_causeAutoimmunity0302 clinical medicine030212 general & internal medicineMutationepitopeautoimmunityGeneral MedicineHLAEuropeviral variantsInfectious DiseasesCoronavirus InfectionsPeptides ; COVID-19 ; Disease association ; Cross-reactivity ; MHC ; T-cells ; Autoimmunity ; Epitope ; Cytokines ; Viral variants ; HLA ; SARS ; SARS-CoV-2 ; MHC bindingMicrobiology (medical)Asia030106 microbiologyPneumonia ViralHuman leukocyte antigenBiologyMajor histocompatibility complexArticlelcsh:Infectious and parasitic diseases03 medical and health sciencesBetacoronavirusMHC class ImedicineHumanslcsh:RC109-216AllelePandemicsAllelesSARSMHC class IISARS-CoV-2T-cellsdisease associationHistocompatibility Antigens Class IHistocompatibility Antigens Class IICOVID-19cytokinesImmunologyAfricabiology.proteinpeptidesMHCInternational Journal of Infectious Diseases
researchProduct

Implications of SARS-COV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease

2021

AbstractGastrointestinal diseases such as celiac disease, functional gastrointestinal disorders (FGIDs), inflammatory bowel disease (IBDs) and acute or chronic diarrhea are quite frequent in the pediatric population. The approach, the diagnosis and management can be changed in the 2019 coronavirus disease (COVID-19) pandemic era. This review has focused on: i) the current understanding of digestive involvement in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected children and adolescents and the clinical implications of COVID-19 for pediatric gastroenterologists, ii) the impact of COVID-19 on the clinical approach to patients with pre-existing or onset diseases, including…

0301 basic medicinemedicine.medical_specialtyAdolescentGastrointestinal Diseasesmedicine.medical_treatmentFunctional gastrointestinal disordersACE2ReviewDiseaseChronic liver diseaseInflammatory bowel diseaseDigestive endoscopyPediatricsGastrointestinal symptomsInflammatory bowel disease03 medical and health sciencesLiver diseaseFunctional gastrointestinal disorder0302 clinical medicineACE2; COVID-19; Digestive endoscopy; Functional gastrointestinal disorders; Gastrointestinal symptoms; Inflammatory bowel disease; Liver disease; Pediatrics; Adolescent; COVID-19; Child; Gastrointestinal Diseases; Humans; Infection Control; SARS-CoV-2Gastrointestinal symptomPandemicmedicineHumansRisk factorIntensive care medicineChildInfection Controlbusiness.industrySARS-CoV-2lcsh:RJ1-570COVID-19lcsh:PediatricsImmunosuppressionmedicine.disease030104 developmental biologyGastrointestinal disease030211 gastroenterology & hepatologybusinessLiver disease
researchProduct

Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19

2020

Since December 2019, a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly engulfed the world. Cancer patients infected with COVID-19 are considered to carry higher severity of the disease and higher mortality rate than common COVID-19 patients in previous studies. However, due to the poor clinical information on COVID-19 patients with cancer, the evidences that supported this conclusion are insufficient. At present, rather limited reports have analyzed the clinical data of breast cancer patients infected with COVID-19. Therefore, in this retrospective study, we described the clinical characteristics and the outcomes of 35 …

0301 basic medicinemedicine.medical_specialtyCancer ResearchCoronavirus disease 2019 (COVID-19)Diseasemedicine.disease_causelcsh:RC254-282Asymptomatic03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineclinical characteristicsCoronavirusOriginal Researchnon-cancerbusiness.industrySARS-CoV-2Mortality rateCancerRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisprognosismedicine.symptombusinessFrontiers in Oncology
researchProduct